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In the last decades, virus-like particles (VLPs) have played an essential role in the development of novel 
vaccines due the fact that they trigger robust and balanced immune responses and, as they lack viral genome, 
are biosafe. Nowadays, several VLPs are commercially available for human use and one veterinary product was 
licensed. Besides, other VLP-based vaccine candidates are in the stages of clinical trials or preclinical 
evaluation. 
 
Our group had previously developed a rabies glycoprotein based-VLP (RV-VLPs) expressed in HEK293 cells. 
These RV-VLPs were fully characterized and their capacity to induce a protective response and neutralizing 
antibodies production was confirmed. As inactivated veterinary vaccines for rabies are usually produced using 
BHK-21, the goal of the present work was to develop a RV-VLPs expressing BHK-21 cell line to analyze the 
characteristics of the VLPs produced using this cell substrate. 
 
Therefore, by lentivirus vector-mediated transduction, we generated a rabies virus glycoprotein expressing a 
stable cell line. The cellular expression of the recombinant protein was analyzed by flow cytometry and the 
membrane localization was confirmed by fluorescent microscopy. Later, RV-VLPs budding to the supernatant 
was analyzed by sandwich ELISA. After that, VLPs were purified by density gradient ultracentrifugation and the 
hydrodynamic diameter of the particles was analyzed by DLS. In a western blot assay, the particles were 
recognized by specific antibodies present in a rabies polyclonal serum. Finally, the recombinant cell line was 
cultured in 850 cm2 roller bottles producing RV-VLPs continuously during 25 days of culture. Thus, these results 
encourage further studies to confirm if BHK-21 is a good cell substrate for the production of RV-VLPs as a 
veterinary rabies vaccine candidate.  
 
 
 
